Owkin partners with Sanofi to build custom AI agents for drug discovery

French AI company Owkin has signed a multi-year collaboration with pharmaceutical giant Sanofi to develop custom AI agents for drug discovery and development. The deal includes a five-year license for Owkin's K Pro platform, which the company describes as an "AI scientist" for pharmaceutical research.

The partnership builds on an existing relationship between the two companies that began in 2021 with a €90 million strategic partnership focused on cancer research and patient analysis. This new agreement represents a significant expansion of their collaboration into what both companies call "agentic AI" - AI systems that can work autonomously to complete complex research tasks.

How will it work?

Owkin will develop specialized AI agents designed specifically for Sanofi's research needs. These agents will operate through the K Pro platform and are intended to work like intelligent assistants that can:

• Perform complex tasks in drug research and development without human intervention
• Analyze multimodal patient data across different stages of pharmaceutical development
• Provide competitive intelligence to inform strategic decisions
• Support research from early discovery through clinical trials

The AI agents will be integrated into Sanofi's existing workflows rather than replacing current systems. K Pro combines patient data analysis with what Owkin calls "specialized biological AI systems" to support decision-making across the pharmaceutical value chain.

Why does it matter?

This partnership reflects a broader trend in pharmaceutical research toward automation and AI-assisted discovery. Drug development is notoriously expensive and time-consuming, with most potential treatments failing before reaching market. AI systems that can autonomously analyze vast amounts of biological data could potentially speed up the discovery process and improve success rates.

The collaboration also signals growing confidence in "agentic AI" - systems designed to work independently rather than just assist human researchers. While many AI applications in pharmaceuticals focus on data analysis and pattern recognition, these agents are designed to actively perform research tasks.

"Building on our collaboration with Sanofi, this marks a shift toward truly embedded AI," said Thomas Clozel, CEO and Co-founder of Owkin. "Owkin believes that, with K Pro, Sanofi can further harness agentic systems within their own workflows, unlocking the full value of their data to accelerate better decisions across drug development."

The context

Owkin positions itself as pursuing what it calls "Biological Artificial Superintelligence" - AI systems that can solve biological problems beyond current human capabilities. The company has been working with pharmaceutical partners for about a decade and maintains what it describes as a large multimodal patient data network.

Sanofi has been investing heavily in AI and digital technologies across its operations. Emmanuel Frenehard, Chief Digital Officer at Sanofi, said the company is "continually investing in frontier AI solutions with the potential to accelerate and improve decision-making throughout the drug development lifecycle."

The pharmaceutical industry has shown increasing interest in AI applications, from drug discovery to clinical trial optimization. However, most current applications focus on specific tasks rather than the kind of autonomous research agents described in this partnership. The success of this collaboration could influence how other pharmaceutical companies approach AI integration in their research processes.